NCT02069145View on ClinicalTrials.gov

Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

May 31, 2017

Study Completion Date

July 31, 2017

Conditions
Hepatocellular CancerLiver Cancer
Interventions
DRUG

OMP-54F28 with Sorafenib

Trial Locations (6)

10029

Mount Sinai Medical Center, New York

19111

Fox Chase Cancer Center, Philadelphia

46202

Indiana University Simon Cancer Center, Indianapolis

80045

University of Colorado Cancer Center, Aurora

90033

USC/Norris Comprehensive Cancer Center, Los Angeles

02114

Massachussetts General Hospital, Boston

Sponsors
All Listed Sponsors
lead

OncoMed Pharmaceuticals, Inc.

INDUSTRY

NCT02069145 - Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer | Biotech Hunter | Biotech Hunter